ChromaGenix is developing a new approach for HCP clearance that selectively retains persistent HCPs while allowing the target product to flow through unbound without an elution step.
Published
Signal category
Products & Services
Quote
“ChromaGenix is developing a different approach: selectively retain persistent HCPs while allowing the target product to flow through unbound.”
— ChromaGenix team
Company
ChromaGenix
Pioneering the new standard of chromatography.
- Industry
- Chemical Manufacturing
- Location
- Raleigh, US
- Company size
- 16 employees
We help biopharma innovators overcome some of the most persistent challenges in drug development: how to purify complex biologics such as AAVs, mRNA, and viral vectors, more efficiently, consistently, and at scale. We specialize in developing synthetic affinity ligands and chromatography resins that are engineered for the production of advanced therapies. Whether you’re working on gene therapy, vaccines, or emerging modalities, ChromaGenix is committed to solving your critical downstream challenges, backed by a culture of innovation, integrity, and scientific rigor.
Founded 2025